MindMed names accomplished pharmaceutical executive, Robert Barrow as its chief development officer

MindMed Inc (NEO:MMED) (OTCQB:MMEDF), has announced the addition of accomplished pharmaceutical executive, Robert Barrow as its chief development officer. The leading psychedelic medicine biotech company noted that Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under the US Food & Drug Administration (FDA) and the European medicines Agency (EMA). In his most recent position, Barrow served as director of Drug Development & Discovery at the Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs in psychedelics. At Usona, he was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA. READ: MindMed announces study to evaluate the effects of daytime and evening administration of low doses of LSD In a statement, MindMed co-CEO J.R. Rahn commented: "Rob has been an integral advisor to MindMed on Project Lucy and in preparing our meetings with the FDA, and we are honored he is now joining us on the senior leadership team. We are excited to attract such top tier talent from the psychedelic drug development community. The entire MindMed team is looking forward to exploring potential additional programs evaluating psilocybin and other psychedelics backed by Rob's recent experience and expertise gaining a breakthrough therapy designation at FDA for a psychedelic-assisted therapy." Barrow added: "Psychedelic therapies offer a once in a lifetime opportunity to revolutionize the delivery of mental healthcare.  In joining MindMed, I look forward to delivering on this potential and working to further build and progress MindMed's pipeline of clinical development programs, offering hope to millions of people suffering from addiction and mental health disorders." Prior to joining Usona, Barrow served as chief operating officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer's Disease and Parkinson's Disease. MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies. Contact the author at jon.hopkins@proactiveinvestors.com